Vectura Group plc. Revenue and Competitors
Estimated Revenue & Valuation
- Vectura Group plc.'s estimated annual revenue is currently $96.5M per year.
- Vectura Group plc.'s estimated revenue per employee is $201,000
Employee Data
- Vectura Group plc. has 480 Employees.
- Vectura Group plc. grew their employee count by -2% last year.
Vectura Group plc.'s People
| Name | Title | Email/Phone |
|---|---|---|
1 | SVP Commercial Operations | Reveal Email/Phone |
2 | SVP - Pharmaceutical Development | Reveal Email/Phone |
3 | SVP - Generic and Analogue Programmes | Reveal Email/Phone |
4 | VP Finance Operations & Transformation | Reveal Email/Phone |
5 | EVP Corporate Strategy and Communication | Reveal Email/Phone |
6 | VP and Head Intellectual Property | Reveal Email/Phone |
7 | SVP - Global Product Leader, Inhaled Therapeutics | Reveal Email/Phone |
8 | SVP, BD&L CDMO | Reveal Email/Phone |
9 | Head Business Systems | Reveal Email/Phone |
10 | Head Financial Operations & Reporting | Reveal Email/Phone |
Vectura Group plc. Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $58.9M | 293 | 6% | N/A | N/A |
#2 | $21.1M | 105 | 5% | N/A | N/A |
#3 | $113.4M | 564 | 1% | N/A | N/A |
#4 | $20.9M | 104 | -5% | N/A | N/A |
#5 | $37M | 184 | 9% | N/A | N/A |
#6 | $45.4M | 226 | -24% | N/A | N/A |
#7 | $16.1M | N/A | N/A | N/A | |
#8 | $69.7M | 347 | 0% | N/A | N/A |
#9 | $8M | 40 | 3% | N/A | N/A |
#10 | $25.5M | 127 | 28% | N/A | N/A |
What Is Vectura Group plc.?
Vectura is a provider of innovative inhaled drug delivery services that enable partners to bring their medicines to patients. With differentiated proprietary technology and pharmaceutical development expertise, Vectura is one of the few companies globally with the device, formulation and development capabilities to deliver a broad range of complex inhaled therapies. \n\nVectura has ten key inhaled and eleven non-inhaled products marketed by partners with global royalty streams, and a diverse partnered portfolio of drugs in clinical development. Our partners include Hikma, Novartis, Sandoz (a division of Novartis AG), Mundipharma, Kyorin, GSK, Bayer, Chiesi, Almirall, and Tianjin KingYork.\n\nFor further information, please visit Vectura's website at www.vectura.com
keywords:N/A
N/A
Total Funding
480
Number of Employees
$96.5M
Revenue (est)
-2%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Vectura Group plc. News
... Rexahn Pharmaceuticals Inc., Savara Inc., Roche Holding AG, Suda Limited, Vectura Group PLC, Taiwan Liposome Company, Ltd., and 3M.
Will was previously CEO of Vectura Group plc, where he spearheaded the transformation of the business into a global leader in the inhaled...
... New Innovative Technologies, Business Opportunities and Forecast to 2021 | AstraZeneca plc, Boehringer Ingelheim GmbH, Vectura Group plc.
Published:10/06/2021 Vectura Group plc, an industry-leading specialist inhalation CDMO, today announces the successful completion of a management buy-out of its oral manufacturing subsidiary in Lyon, Skyepharma Production SAS. In 2019, Vectura Group made the strategic decision to become a full ...
Published:21/04/2021 Vectura Group highlights the announcement made today by Hikma Pharmaceuticals PLC regarding its launch of generic Advair Diskus®. Hikma Pharmaceuticals PLC today posted the following statement: 'Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, ...
Other Companies in Chippenham
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $121.8M | 606 | 4% | N/A |
#2 | $35M | 1244 | 8% | N/A |
#3 | $3305M | 7740 | 5% | N/A |